



FORM: Request for HIPAA Waiver of Authorization

Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 2 of 6

3. Select all of the identifiers that will be used in this research

<input type="checkbox"/> Names	<input type="checkbox"/> Vehicle Identification/License Plate numbers
<input type="checkbox"/> Addresses including ZIP	<input type="checkbox"/> Account numbers
<input type="checkbox"/> All date (except year) and ages over 89	<input type="checkbox"/> Biometric identifiers
<input type="checkbox"/> Telephone numbers	<input type="checkbox"/> Device identifiers
<input type="checkbox"/> Fax numbers	<input type="checkbox"/> Full face photos & any comparable images
<input type="checkbox"/> Social Security Numbers	<input type="checkbox"/> URLs
<input type="checkbox"/> Medical Record Numbers	<input type="checkbox"/> IP Addresses
<input type="checkbox"/> Health plan numbers	<input type="checkbox"/> Email addresses
<input type="checkbox"/> Certificate/License numbers	<input type="checkbox"/> Any other unique identifying number, characteristic, or code (except those assigned by an investigator to code the data)

Partial Waiver of Authorization

1. The use or disclosure of Protected Health Information (PHI) involves no more than minimal risk to the privacy of individuals. Describe how the use of PHI in this research poses no greater than minimal risk to participants' privacy.

2. Describe the plan to protect identifiers and indicate where PHI will be stored and who will have access (list all entities that might have access to the PHI such as IRB, sponsors, FDA, data safety monitoring boards, and any others given authority by law).



FORM: Request for HIPAA Waiver of Authorization

Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 3 of 6

3. Describe the plan to destroy the participant identifiers at the earliest opportunity consistent with the recruitment procedures, unless retention is required for reasons of health, research, or law. Please explain if the participant identifiers will be stored or retained and the length of time they will be stored or retained:

4. Recruitment for this research could not practicably be conducted without a partial waiver of authorization because:

5. Recruitment for this research could not practicably be conducted without access to and use of the PHI because:



FORM: Request for HIPAA Waiver of Authorization

Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 4 of 6

Waiver of Authorization

1. The use or disclosure of Protected Health Information (PHI) involves no more than minimal risk to the privacy of individuals. Describe how the use of PHI in this research poses no greater than minimal risk to participants' privacy.

2. Describe the plan to protect identifiers and indicate where PHI will be stored and who will have access (list all entities that might have access to the PHI such as IRB, sponsors, FDA, data safety monitoring boards, and any others given authority by law).



FORM: Request for HIPAA Waiver of Authorization

Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 5 of 6

3. Describe the plan to destroy the participant identifiers at the earliest opportunity consistent with the conduct of research, unless retention is required for reasons of health, research, or law. Please explain if the participant identifiers will be stored or retained and the length of time they will be stored or retained:

4. The research could not practicably be conducted without the waiver because:

5. The research could not practicably be conducted without access to and use of the PHI because:



FORM: Request for HIPAA Waiver of Authorization

Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 6 of 6

PI Assurances

In applying for a waiver of authorization or partial waiver of authorization, I agree to the following:

- A) The identifiers used for this research study will not be used for any other purpose or disclosed to any other person or entity (aside from members of the research team identified in the research application), except as required by law.
- B) If at any time I want to reuse this information for other purposes or disclose the information to other individuals, I will seek approval from the IRB.
- C) I will comply with AdventHealth HIPAA policies and procedures and with the use and disclosure restrictions describes above.

I assume responsibility for all uses and disclosures of the PHI by members of the study team.

Date:

Principal Investigator Signature: